<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04140318</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2070</org_study_id>
    <nct_id>NCT04140318</nct_id>
  </id_info>
  <brief_title>Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma</brief_title>
  <official_title>Efficacy and Safety of Sintilimab and Nab-paclitaxel in Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma Patients With Progression After Fluoropyrimidine or Platinum, a Multi-center, Phase II, Single Arm Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Sintilimab (PD-1 inhibitor) and nab-paclitaxel in&#xD;
      second line treatment of advanced gastric and gastro-esophageal junction adenocarcinoma. This&#xD;
      is a prospective, multi-centers, single arm phase II trial with primary objective overall&#xD;
      response rate and second objective of safety and other efficacy endpoints.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>up to three years</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>up to three years</time_frame>
    <description>duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>from first dose to 90days of last dose</time_frame>
    <description>treatment related adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to three years</time_frame>
    <description>progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to three years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination therapy of PD-1 and chemotherapy including: sintilimab 200mg iv, 30-60min, q3w; nab-paclitaxel 125mg/m2, iv, d1,d8, q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sintilimab</intervention_name>
    <description>Sintilimab 200mg, iv, 30-60min, q3w;</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Nab-paclitaxel: 125 mg/m2 iv d1、d8, q3w</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pathological confirmed advanced gastric and gastro-esophageal junction adenocarcinoma;&#xD;
&#xD;
          -  progression after first-line treatment of fluoropyrimidine and platinum, allow&#xD;
             patients progressed on/within 6 months of neoadjuvant/adjuvant treatment; allow local&#xD;
             radiotherapy after 21days later;&#xD;
&#xD;
          -  18-75 years old;&#xD;
&#xD;
          -  ECOG: 0 or 1;&#xD;
&#xD;
          -  has adequate organ function&#xD;
&#xD;
          -  writen ICF;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous treated with taxanes (including paclitaxel, nab-PTX, lipo-PTX, and docetaxel&#xD;
             etc..);&#xD;
&#xD;
          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody;&#xD;
&#xD;
          -  has known active central nervous system metastatases;&#xD;
&#xD;
          -  has received a live vaccine within 4 weeks prior to the first dose of study treatment&#xD;
             with any acitve autoimmune disease or history of autoimmune disease, including but not&#xD;
             limited to the following: hepatititis, pneumonitis, uveitis, colitis (inflammatory&#xD;
             bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and&#xD;
             hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy.&#xD;
             Asthma that requires intermittent use of bronchodilators or other medical intervention&#xD;
             should also be excluded.&#xD;
&#xD;
          -  clinically significant cardiovascular and cerebrovascular diseases, including but not&#xD;
             limited to severe acute myocardial infarction within 6 months before enrollment,&#xD;
             unstable or severe angina, Congestive heart failure (New York heart association (NYHA)&#xD;
             class &gt; 2), orventricular arrhythmia which need medical intervention.&#xD;
&#xD;
          -  hypertension and unable to be controlled within normal level following treatment of&#xD;
             anti-hypertension agents(within 3 months): systolic blood pressure &gt; 140 mmHg,&#xD;
             diastolic blood pressure &gt; 90 mmHg. coagulation abnormalities (INR &gt; 1.5 or APTT &gt;&#xD;
             1.5×ULN), with bleeding tendency or are receiving thrombolytic or anticoagulant&#xD;
             therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aiping Zhou, MD</last_name>
    <phone>8687788145</phone>
    <email>zhouap1825@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>10000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ai ping Zhou</last_name>
      <phone>8610-87788145</phone>
      <email>zhouap1825@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Aiping Zhou</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>second line</keyword>
  <keyword>PD-1</keyword>
  <keyword>nab-paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The baseline characteristics of patients could be shared to othter researchers per request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

